Feature | November 14, 2013

Mayo Clinic Studying Genomics of Antiplatelet Heart Medication

Participant DNA biobank to help elucidate genomics of coronary artery disease

November 14, 2013 — Professional cardiovascular societies and many working cardiologists question the U.S. Food and Drug Administration’s (FDA’s) recent recommendation that patients undergo genetic testing before taking Plavix (clopidogrel bisulfate).
 
The Tailored Antiplatelet Therapy to Lessen Outcomes after Percutaneous Coronary Intervention (TAILOR-PCI) study, launched this summer by the Center for Individualized Medicine and the Division of Cardiovascular Diseases at Mayo Clinic, examines whether prescribing heart medication based on a patient’s CYP2C19 genotype will help prevent heart attack, stroke, unstable angina and cardiovascular death in patients who undergo angioplasty.
 
“The current standard of care after angioplasty is to prescribe clopidogrel for one year, regardless of a person’s individual genotype, even though we have known for several years that variation in the CYP2C19 gene may diminish the benefit from the drug,” said Pereira, M.D., cardiologist, Mayo Clinic and principal investigator of TAILOR-PCI. “What we don’t know — and why there is such confusion in the cardiovascular community — is how these genetic changes affect long-term clinical outcomes and whether we can decrease overall health care costs.”
 
Plavix remains ineffective until the liver enzyme CYP2C19 metabolizes the drug into its active form. Some alternative medications, including Brilinta (ticagrelor), do not require activation through the same genetic pathway.
 
“Ticagrelor has its own risks, including serious or life-threatening bleeding,” said Pereira. “Additionally, this alternative therapy costs approximately six to eight times as much and must be taken twice a day. Ultimately, what we’re trying to do with TAILOR is use pharmacogenomics to determine whether choosing medication based on individual genotype will help patients live longer and whether the benefits will outweigh the risks of alternative therapies.”
 
Nilay Shah, Ph.D., associate professor of health services research, Mayo Clinic Health Sciences, will study potential cost impacts to the health care system.
 
“This study examines as much as an $8 billion question in health care,” said Shah. “Clopidogrel is the second-most prescribed medication in the United States, and although ticagrelor costs much more, the costs of taking patients into the emergency room and performing a second angioplasty are much higher.”
 
Another additional benefit of the study will be creation of a coronary artery disease (CAD) biobank containing DNA samples from the study’s 5,300 participants. Researchers at Mayo Clinic and elsewhere can mine these samples and use genomic sequencing technologies to help further medicine’s understanding of the origins of and risk factors for coronary heart disease.
 
“TAILOR-PCI is exactly the type of research we do every day — the kind that translates into better health for our patients and improves the delivery of care for millions of patients around the world,” said Gianrico Farrugia, M.D., director, May Clinic Center for Individualized Medicine.
 
Up to one-third of patients currently taking Plavix (up to half of some Asian populations) have a genomic variant implicated in diminished drug response. Study teams at 15 hospitals in three countries have teamed up to enroll 5,300 patients into TAILOR-PCI and deliver results in three years. The Pharmacogenomics Program in the Center for Individualized Medicine administers this study.
 

Related Content

DEFUSE-2 study, MRI, brain bleeding risk, post-stroke treatment, NIH

This image combines pre- and post-treatment scans from the same patient. Analysis of the two scans revealed that the area and size of post-treatment bleeding corresponded to blood-brain barrier disruption (shown in green, yellow and red) prior to therapy. Image courtesy of Richard Leigh, NINDS.

News | Stroke| June 29, 2016
In a study of stroke patients, investigators confirmed through magnetic resonance imaging (MRI) brain scans an...
Sponsored Content | Videos | Cardiovascular Ultrasound| June 28, 2016
Interview with Rebecca Hahn, M.D., FASE, Columbia University Medical Center, New York, at the American Society of Ech
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
CT scans, cancer risk, radiation dose, Canadian study
News | Computed Tomography (CT)| June 27, 2016
June 27, 2016 — A new study in the Journal of Medical Imaging and Radiation Sciences surveyed doctors, radiologists a
atrial fibrillation, stroke risk, aspirin vs blood thinners, JACC study
News | Antiplatelet and Anticoagulation Therapies| June 24, 2016
More than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated with aspirin...
News | Cardiac Diagnostics| June 24, 2016
Measuring antibody levels in the blood could be used to detect a person’s heart attack risk after researchers, part-...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
Sponsored Content | Videos | Structural Heart Occluders| June 16, 2016
This is an animation of how a Gore Cardioform Septal Occluder is implanted for the transcatheter closure of ASDs or P
News | Implantable Cardioverter Defibrillators (ICD)| June 14, 2016
Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter...
hypertrophic cardiomyopathy, HCM, strain echocardiography, risk assessment, ASE 2016
News | Cardiovascular Ultrasound| June 13, 2016
After following a large sub-set of patients, researchers found that by using strain echocardiography they could...
Overlay Init